Stifel Nicolaus Issues Pessimistic Forecast for Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price

Bolt Biotherapeutics (NASDAQ:BOLT) had its price target reduced by equities researchers at Stifel Nicolaus from $1.50 to $1.25 in a report released on Tuesday,Benzinga reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 184.09% from the company’s previous close.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ:BOLT opened at $0.44 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. The business’s fifty day moving average price is $0.47 and its two-hundred day moving average price is $0.56. Bolt Biotherapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.56. The stock has a market capitalization of $16.84 million, a price-to-earnings ratio of -0.26 and a beta of 0.94.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, hitting the consensus estimate of ($0.38). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.79 million. As a group, analysts predict that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Millennium Management LLC bought a new stake in Bolt Biotherapeutics during the 4th quarter worth approximately $25,000. Squarepoint Ops LLC acquired a new position in Bolt Biotherapeutics in the fourth quarter worth $26,000. Velan Capital Investment Management LP bought a new stake in shares of Bolt Biotherapeutics during the fourth quarter worth $27,000. Citadel Advisors LLC bought a new stake in shares of Bolt Biotherapeutics during the fourth quarter worth $42,000. Finally, FMR LLC increased its stake in shares of Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares in the last quarter. Institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.